Supergenics Share Price

03033

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA Other stock markets 02:20:01 30/12/2025 pm IST			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

30/04	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
27/02	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Stock Market
Stocks
03033 Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	2.91Cr 71.07L 62.11L 57.31L 52.83L 99.57L 68Cr 1.02Cr 6.85Cr 2.69Cr 34Cr 2.67Cr 2.61Cr 115.39Cr	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	3.25Cr 79.36L 69.35L 63.99L 58.99L 1.11Cr 76Cr 1.14Cr 7.65Cr 3.01Cr 37Cr 2.98Cr 2.91Cr 128.84Cr	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

30/04	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
27/02	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/12	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/25/29	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/25/27	Supergenics fixes issue price at 0.27 RGT per share	RE
12/25/12	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/25/21	Supergenics Berhad Announces Change of Registered Office Address	CI
28/25/28	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/24/30	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/24/02	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/24/29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/24/29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/24/06	41,850,000 Ordinary Shares of Supergenics Berhad are subject to a Lock-Up Agreement Ending on 6-JAN-2024.	CI

1 year	0.2	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	24/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	02/06/2022

Director	Title	Age	Since
Bii Chau Tan BRD	Director/Board Member	48	24/04/2019
Fun Kim Ng BRD	Director/Board Member	60	24/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	28/01/2022

Supergenics Share Price

Stocks

03033

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news : Supergenics

Quotes and Performance

Course Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	-16.67%	+13.64%	71.07L
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	3.96TCr
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	3.47TCr
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	3.44TCr
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	2.71TCr
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	1.62TCr
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	1.54TCr
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	1.41TCr
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	1.3TCr
ABIVAX	-0.08%	-3.01%	+1,271.69%	+649.69%	1.18TCr
Average	+2.37%	+0.03%	+196.44%	+161.05%	2.06TCr
Weighted average by Cap.	+0.24%	+0.36%	+171.42%	+187.41%

	2024	2025
Net sales	53.22L 12.99L 11.35L 10.48L 10L 18.2L 13Cr 18.61L 1.25Cr 49.26L 6.13Cr 48.8L 47.73L 21Cr	56.25L 13.73L 12L 11.08L 10.21L 19.24L 13Cr 19.67L 1.32Cr 52.07L 6.48Cr 51.58L 50.45L 22Cr
Net income	-72.81L -17.78L -15.54L -14.34L -13.21L -24.91L -17Cr -25.46L -1.71Cr -67.39L -8.38Cr -66.76L -65.3L -29Cr	-33.66L -8L -7L -7L -6L -11.51L -7.91Cr -11.77L -79.2L -31.15L -3.88Cr -30.86L -30.18L -13Cr
Net Debt	44.77L 10.93L 10L 9L 8L 15.31L 11Cr 15.65L 1.05Cr 41.44L 5.16Cr 41.05L 40.15L 18Cr	33.94L 8L 7L 7L 6L 11.61L 7.98Cr 11.87L 79.87L 31.42L 3.91Cr 31.12L 30.44L 13Cr